CasNo.366789-02-8,Rivaroxaban Tablet Raw Material Powder CAS 366789-02-8 Rivaroxaban,Rivaroxaban(366789-02-8) Suppliers

0	Negotiable

Min.Order :0
Purity: 99%

Keywords

Rivaroxaban Rivaroxaban powder 366789-02-8

Quick Details

Appearance:White to off-white crystal powder
Application:1.Rivaroxaban can be used to prevent strokes in those with atrial fibrillation due to causes other than heart valvedisease, and at least one additional risk factor for stroke (congestive heart fai...
PackAge:Aluminum foil bag,fluorinated bottles,carboard drums or as your special request.
ProductionCapacity:
Storage:Store in cool & dry place. Keep away from strong light Shelf Life2 years when properly stored.
Transportation:1) Door to Door Service by DHL/FEDEX/EMS/TNT for package under 45kgs, about 3~7 days delivery. 2) Port to Port Service by Air for package more than 45kgs, about 3~7 days delivery. 3) Port to Port...

Superiority:

1) Provide costomers with "one-stop"packaging service,from research,development,production,export and so on.
2) We have our own R&D and production base,equipped with advanced production equipment and precision testing the Unitef States Pharmacopoeia(USP),the Britis Pharmacopoeia(EP) and other international advanced standards.All products are through the KOSGER,HALAL certification,the ISO quality management system certification and the HACCP certification.
3) More than 12 years of export experience.
4)Competitive price in China market.

Details:

Rivaroxaban and pekah ester group is currently the most promising two antithrombotic drugs, and the essential difference between traditional antithrombotic drug heparin is that it does not need antithrombin Ⅲ participation, free and can be directly antagonism Xa factor. Whereas heparin requires antithrombin Ⅲ can play a role, and prothrombin complex of Xa factor is invalid. These two kinds of new type of oral anticoagulant drugs by the medical profession as anticoagulant therapy and potentially deadly blood clots, a significant progress in the field of prevention will be a new milestone in the history of cardiovascular drugs.